César Serrano García, Group Leader of VHIO´s Sarcoma Translational Research Group, shared a post on X:
“mTOR and/or PI3K inhibitors can be an effective treatment in GIST SDH-deficient
Activating mutations in the PI3K/mTOR pathway in relapsed/mts samples
Sustained 55-months response with everolimus
We provide other insights on tumor evolution.”
Authors: Carlo María Cicala et al.
